The publisher
About Order PT-141.
A publisher that sets the PT-141 (bremelanotide) research record in order — and is careful about what it is, and what it is not.
What this project is
Order PT-141 is a publishing project built around one task: assembling the peer-reviewed research on PT-141 (bremelanotide) into a single, orderly record. It runs no clinic and keeps no medical staff; it offers no diagnosis, no dose guidance, and no treatment advice; and it makes, stocks, and ships nothing. What appears here is an account of published science, cited throughout.
The method is the one the name implies — set the record in order. The compound sits in a corner of the internet thick with sales pitches and sensational claims, and the work here runs the other way: arrange what the trials measured, state the approval scope precisely, put the tolerability cost in plain view, and mark the places where the data stop. Every quantitative clinical claim points to a primary source.
What 'order' means here, and what it does not
The word "order" here means putting the literature in order — arranging the evidence into a composed, readable record. It has nothing to do with a purchase. No price is listed, no inventory is held, no vendor is named; the name is a description of the editorial stance, not a shopfront.
That distinction governs the whole site. The bremelanotide label dose is reported as a documented finding, never as a regimen for a reader to follow. The off-label male research is summarized as investigational, never as settled. And community anecdote is quarantined in a single, clearly labeled field-reports section held structurally apart from the cited evidence, so the two are never taken for one another.
How the sourcing works
The clinical material rests on the primary record: the RECONNECT Phase 3 trials and their long-term extension, the mechanistic neuroimaging study, the foundational melanocortin pharmacology, the bremelanotide prescribing information, the Phase 1 metabolic work, and the critical re-analyses arguing the effect is modest. Recent 2024-2025 studies and reviews are included with their evidence tier noted. The full list sits on the study references page.
Where the literature disagrees — most visibly on how meaningful the desire effect is — both sides are laid out rather than settled for the reader. An honest record is worth more than a tidy one.